The Most Favored Nation (MFN) Executive Order aims to reset global drug pricing structures, centering pricing policies around the U.S. patient base. Despite its ambitious scope, the order’s implementation faces uncertainties concerning enforcement, legal authority, and the requisite international collaboration. The policy represents a pivotal development in U.S. pharmaceutical regulation with potential far-reaching industry effects, yet its operational outcome remains uncertain, as analyzed in MedCity News.